MedTrace Logo

Low-level Laser Therapy in Wrist Fractures

NCT02749929 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2021-04-30

No results posted yet for this study

Summary

Approximately 15,000 persons in Norway suffer from wrist fractures during a year, making it the most prevalent fracture in this country. Treated conservatively, a cast is used for 4-6 weeks before removal. After discontinuation of the cast, physiotherapy is implemented to aid in improving range of motion and regaining function of the injured wrist. The pain after injury can affect the patient to a greater or lesser extent, and it is common to prescribe sick leave for shorter amounts of time after the injury.

Studies suggest that a physiotherapy intervention with Low Level Laser therapy (LLLT) may reduce pain and swelling after acute trauma, and potentially promote healing. The aim of this study is to evaluate the effect of LLLT on pain and function at 2, 4, 8 and 26 weeks after injury.

Conditions

  • Colles' Fracture

Interventions

OTHER

Low level laser therapy

The laser is an infrared (invisible) 60 mW 904 nm Irradia Midlaser

OTHER

Placebo Low Level Laser Therapy

The placebo laser is an identical device to the active laser, made by Irradia Midlaser

Sponsors & Collaborators

  • Norwegian Fund for Postgraduate Training in Physiotherapy

    collaborator OTHER

  • University of Bergen

    lead OTHER

Principal Investigators

  • Jan Magnus Bjordal, Professor · University of Bergen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2020-11-30
Completion
2021-04-27

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02749929 on ClinicalTrials.gov